Contract Manufacturing

With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. 

Following extensive talks, leading pharmaceutical companies sign an agreement to work with renewable energy companies to decarbonise their manufacturing supply chains in China and switch to renewables. 

NextPharma has completed their acquisition of a Norway-based manufacturing site, specialising in chewable tablet technologies for calcium/vitamin D3 from pharmaceutical giant Takeda.

CordenPharma, the CDMO specialising in APIs, lipid excipients, and drug products, signs a new billion dollar contract to expand its manufacturing capabilities. 

A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country.

Thermo Fisher Scientific are to open a new cGMP facility in China, including the latest technology so that they can assist in the accelerated provision of medicines to patients. 

Aragen is set to open their new manufacturing facility at their Mallapur campus in Hyderabad, India in January 2023, enhancing the company’s ability to provide scaled manufacturing solutions and clinical supplies to their customers.

The major expansion of Quotient Sciences’ drug substance manufacturing facility in Alnwick has been completed, promising increased manufacturing systems and capabilities. 

Quotient Sciences’ Nottingham and Reading facilities have announced the completion of their facility expansions, providing further capabilities to support their flagship program Translational Pharmaceutics®.

Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities.

Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma.